Compete against established giants and scrappy upstarts to launch a new, novel toothpaste. We’re long-term subscribers ... In compiling a recent case for long-term, sustained investment in brand, we ...

The facility was previously upgraded five years ago with a nearly $17 million investment by Haleon predecessor GSK, which merged with Pfizer ... for research and development for its brands that ...

The U.S. Food and Drug Administration (FDA) approved GSK's combination vaccine to protect against meningococcal infection for ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Toothpaste is crucial for maintaining dental health, preventing issues like gingivitis and ensuring white, shiny teeth. Regular brushing helps make a good impression and supports overall well-being by ...

Haleon, an international manufacturer of medicine, vitamins and toothpaste, will upgrade its ... two other pharmaceutical giants, Pfizer and GSK, spun off their consumer health care businesses ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK does not need a miracle cure — just some rest and rehabilitation. Investors, though, seem unwilling ...